drugset / Trial / NCT02251145

Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

NCT02251145

Phase 1 Completed 49 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to characterise the effects of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered BID, on the pharmacokinetics of tenofovir disoproxil fumarate as well as the effects of tenofovir disoproxil fumarate on the pharmacokinetics of tipranavir/ritonavir.

Timeline

Start
2002-05
Primary completion
2002-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg
Subject Tenofovir disoproxil fumarate Small molecule 300 mg
Subject Tipranavir Small molecule 500 mg
Subject Tipranavir Small molecule 750 mg

Indications

No indication recorded.